troglitazone has been researched along with thapsigargin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujishima, M; Hirano, K; Hirano, M; Kanaide, H; Kawasaki, J; Nishimura, J | 1 |
| Furuse, Y; Hisatome, I; Ogino, K; Sasaki, N; Shimoyama, M | 1 |
2 other study(ies) available for troglitazone and thapsigargin
| Article | Year |
|---|---|
Troglitazone inhibits the capacitative Ca2+ entry in endothelial cells.
Topics: Adenosine Triphosphate; Animals; Aorta; Bradykinin; Calcium; Calcium Channel Blockers; Cells, Cultured; Chromans; Diltiazem; Endothelin-1; Endothelium, Vascular; Enzyme Inhibitors; Imidazoles; Swine; Thapsigargin; Thiazoles; Thiazolidinediones; Time Factors; Troglitazone; Vasodilator Agents | 1999 |
Ca(2+)-sensitizing effect is involved in the positive inotropic effect of troglitazone.
Topics: Animals; Calcium; Calcium Channels, L-Type; Cardiotonic Agents; Chromans; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Heart Ventricles; Isoproterenol; Male; Patch-Clamp Techniques; Rats; Rats, Wistar; Ryanodine; Sarcoplasmic Reticulum; Thapsigargin; Thiazoles; Thiazolidinediones; Troglitazone; Ventricular Pressure | 2001 |